French early nationwide idecabtagene vicleucel chimeric antigen receptor T‐cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real‐world IFM study from the DESCAR‐T registry.

MLA

Ferment, B., et al. “French Early Nationwide Idecabtagene Vicleucel Chimeric Antigen Receptor T‐cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): A Real‐world IFM Study from the DESCAR‐T Registry.” British Journal of Haematology, vol. 205, no. 3, Sept. 2024, pp. 990–98. EBSCOhost, https://doi.org/10.1111/bjh.19505.

APA

Ferment, B., Lambert, J., Caillot, D., Lafon, I., Karlin, L., Lazareth, A., Touzeau, C., Leleu, X., Moya, N., Harel, S., Perrot, A., Bories, P., Vincent, L., Lamure, S., Mohty, M., Malard, F., Manier, S., Yakoub, A. I., Schiano, D. C. J. ‐M., & Brisou, G. (2024). French early nationwide idecabtagene vicleucel chimeric antigen receptor T‐cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real‐world IFM study from the DESCAR‐T registry. British Journal of Haematology, 205(3), 990–998. https://doi.org/10.1111/bjh.19505

Chicago

Ferment, B., J. Lambert, D. Caillot, I. Lafon, L. Karlin, A. Lazareth, C. Touzeau, et al. 2024. “French Early Nationwide Idecabtagene Vicleucel Chimeric Antigen Receptor T‐cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): A Real‐world IFM Study from the DESCAR‐T Registry.” British Journal of Haematology 205 (3): 990–98. doi:10.1111/bjh.19505.